Default: Diabetes, Obesity and Metabolism

ISSN: 1462-8902

Journal Home

Journal Guideline

Diabetes, Obesity and Metabolism Q1 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Diabetes, Obesity and Metabolism is a journal indexed in SJR in Endocrinology and Endocrinology, Diabetes and Metabolism with an H index of 128. It has a price of 3857 €. It has an SJR impact factor of 2,445 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,445.

Diabetes, Obesity and Metabolism focuses its scope in these topics and keywords: diabetes, type, insulin, review, management, glargine, adjustment, inhibitors, randomized, systematic, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Metrics

Diabetes, Obesity and Metabolism

2,445

SJR Impact factor

128

H Index

301

Total Docs (Last Year)

989

Total Docs (3 years)

11144

Total Refs

5621

Total Cites (3 years)

934

Citable Docs (3 years)

5,48

Cites/Doc (2 years)

37,02

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


diabetes, type, insulin, review, management, glargine, adjustment, inhibitors, randomized, systematic, metformin, levels, people, patients, mellitus, programme, safety, adipocyte, artificial, arterial, amyloid, atherosclerotic,



Best articles by citations

Testosterone and leptin in a group of Chinese with and without diabetes

View more

Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project

View more

Editorial

View more

Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia

View more

Isolation of human islets and beta-cells for pharmacological studies

View more

Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus

View more

Influence of a combination of herbs on appetite suppression and weight loss in rats

View more

What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE

View more

Lack of postprandial leptin peaks in patients with type 2 diabetes mellitus

View more

FDA reviews troglitazone

View more

N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice

View more

Is insulin resistance the principal cause of type 2 diabetes?

View more
SHOW MORE ARTICLES

News and views

View more

News and views

View more

Acute physiological effects of glucocorticoids on fuel metabolism in humans are permissive but not direct

View more

A new hope in the nightmare of diabetic orthostatic hypotension: the midodrine-fludrocortisone association

View more

Sudden death in type 1 diabetes

View more

In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery

View more

Antilipolytic drugs for the prevention of primary ventricular fibrillation

View more

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes

View more

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

View more

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

View more

Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project

View more

Do baseline serum leptin levels predict weight regain after dieting in obese women?

View more

FAQS